|
Department of Pharmacy
Professor
Tatsuji Iga, Ph.D.
Associate Professor
Yasuhiko Yamada, Ph.D. (-2003.3) Hiroshi Suzuki, Ph.D. (2003.4-)
Lecturer
Takao Aoyama, PhD.
Research Associate
Takahiro Kubota, Ph.D. Yoshitsugu Yanagihara, Ph.D.
Takeshi Ozeki, Ph.D. (-2003.12) Tomonobu Uchino, Ph.D.
Kazuo Takayama, M.S. Erika Sugiyama, M.S.
Makiko Kusama, M.S. Takehito Yamamoto, M.S. (2004.3-)
Organization
The Department of Pharmacy consists of the following four sections: the
dispensing section, manufacturing section, drug information and clinical testing
section, and the inventory section. Ten faculty members are taking part in
educational and research activities as well as clinical activities. We also have
47 pharmacy staffs, 20 pharmacy residents, and 8 graduate students from the
university's Graduate School of Pharmaceutical Sciences (fiscal year 2003).
Educational Activities
The Department of Pharmacy have been providing clinical practices for both
medical and pharmacy students and also for some graduates. In addition, we hold
continuing education seminars (5 times a year) and compounding workshops (once a
month) for pharmacists.
Interdisciplinary education is important in training healthcare professionals to
promote safer and more effective therapy. We have been tutoring forth year
medical students for BSL (Bed-Side Learning). During the one-week period, they
learn some basic skills that will be required in their future career, such as
writing prescriptions, collecting adequate drug information, and risk management
in using medications. It is nearly their first time to learn about clinical
pharmacokinetics and therapeutic drug monitoring (TDM). Furthermore, they will
learn about the general pharmaceutical care that we provide, such as formulation
of in-hospital suppositories and ointments, etc., filling and checking of
prescriptions, and the drug supplying system. We have been experiencing that
appreciation of our pharmaceutical care is helpful for both of us in promoting
safe and effective therapy in interdisciplinary teams as the students become our
resident physicians.
We hold a total of 2-week practice for the students of the university's Faculty
of Pharmaceutical Sciences. Although most students do not choose pharmacists as
their first career, the students will learn about the general pharmaceutical
care for a better understanding of applied pharmaceutical science. We also hold
two series of lectures for the undergraduate students (Clinical Pharmacy I, II;
1 credit each), and for the graduate students (2 credits) in the Graduate School
of Pharmaceutical Sciences.
Research Activities
The ultimate goal in our research activities is optimization of drug therapy.
The faculty staffs are performing various studies, and tutors graduate and
undergraduate students from the Faculty of Pharmaceutical Sciences as well as
pharmacy staffs and pharmacy residents.
We have focused on genetic polymorphisms of metabolizing enzymes and its
phenotype, population pharmacokinetic analysis for individualized therapy, and
research and development of in-hospitail preparations and methodology that could
raise the patient QOL. The following are the main projects that we are engaged
in:
1) Analysis on genetic polymorphisms on drug metabolizing enzymes and other
factors on the evaluation on individual and sex variation of medications
1)-1 Exploratory research of new SNPs (single nucleotide polymorphisms) and
statistical analysis of genetic polymorphisms in the Japanese population (Cytochrome
P450 [CYP2D6, CYP3A4, and CYP3A5], GST (glutation S-transferase), and NAT2 (N-acetyltransferase
2))
1)-2 Relationship between genetic polymorphisms of drug metabolizing enzymes and
the influence on pharmacokinetics of drugs
1)-3 Pharmacodynamic analysis of sex difference
2) Research and development of in-hospital preparations
3) Clinical and practical studies on optimization of drug therapy
Clinical Activities
We provide pharmaceutical care through 4 sections listed below. Conferences are
held every Tuesday evening for updating drug information and for continuing
education.
1) Dispensing Section
After inspecting all prescriptions for contraindications or improper use,
medications are dispensed. Drug information is given to outpatients from this
section, sometimes using a private room. A computerized order entry system is
linked with automatic packaging machines for oral medicines, and bar code label
printer and automatic dispensing system for injection drugs. The bar code labels
will be used for safety management in administration of injection drugs.
2) Manufacturing Section
Medications that are commercially unavailable and/or have some problems in
stability are prepared for clinical and research use. They are clinically
applied after approval from the institutional ethical committee.
3) Drug Information and Clinical Testing Section
This section collects, evaluates, analyzes, and provides up-to-date drug
information for pharmacists and other health care professionals. Periodical
in-hospital newsletters and booklets are published. Also, this section prepares
data for the institutional pharmaceutical committee, which decides the hospital
formulary. The clinical testing section implements quality tests of drugs that
are prepared in the hospital. Therapeutic drug monitoring (TDM), which is
successful in providing rational therapy, such as infection diseases and
post-transplantation therapy, is carried out in this section.
4) Inventory Section
The pharmacy is responsible for the inventory management and provides
approximately 2000 medications with the least dead stock. We also confirm that
we comply with the GPMSP application. The Narcotics Control Center is in charge
of the management of the narcotic agents, which is strictly regulated by the
law. The amount of narcotic agents used is increasing along with the demands for
better pain control.
Statistical Data (fiscal year 2002)
Number of items on in-hospital formulary: approx. 2000
Number of prescriptions filled (annual)
out-patients: 492,795
in-patients 382,106
(oral and external): 171,804
(injection drugs): 176,505
(IVH): 27,706
(chemotherapy): 6,091
TDM consultations (annual): 12,545
Numbers of Clinical Consulting (out-patients; annual): 64,195
References
- Frequent occurrence of CYP2D6*10 duplication allele in a Japanese
population. Mitsunaga Y., Kubota T., Ishiguro A., Yamada Y., Sasaki H.,
Chiba K., and Iga T. Mutat Res. 505: 83-85 (2002)
- Thiopurine S-methyltransferase activity in Japanese subjects: metabolic
activity of 6-mercaptopurine 6-methylation in different TPMT genotypes.
Nishida A., Kubota T., Yamada Y., Higashi K., Kitamura K., Nakahara K., and
Iga T. Clin Chim Acta. 323: 147-150 (2002)
- Prediction and assessment of extrapyramidal side effects induced by
risperidone based on dopamine D2 receptor occupancy. Yamada Y., Ohno Y.,
Nakashima Y., Fukuda M., Takayanagi R., Sato H., Tsuchiya F., Sawada Y., and
Iga T. Synapse 46: 32-37 (2002)
- A new method for determination of buformin in plasma and urine by
ion-paired reversed-phase HPLC with ultraviolet detection. Yamamoto T.,
Kusama M., Matsuno K., Sugiyama E., Yamada Y., and Iga T. Biomed Chromatogr.
16: 453-454 (2002)
- Cosmetic color improvement of the nipple-areola complex by optimal use
of tretinoin and hydroquinone. Yoshimura K., Momosawa A., Watanabe A., Sato
K., Matsumoto D., Aiba E., Harii K., Yamamoto T., Aoyama T., and Iga T.
Dermatol Surg. 28: 1153-1157; discussion 1158 (2002)
- Plasma concentration profiles of ketamine and norketamine after
administration of various ketamine preparations to healthy Japanese
volunteers. Yanagihara Y., Ohtani M., Kariya S., Uchino K., Hiraishi T.,
Ashizawa N., Aoyama T., Yamamura Y., Yamada Y., and Iga T. Biopharm Drug
Dispos. 24: 37-43 (2003)
- Clinical trial of bleaching treatment with 10% all-trans retinol gel.
Yoshimura K., Momosawa A., Aiba E., Sato K., Matsumoto D., Mitoma Y., Harii
K., Aoyama T., and Iga T. Dermatol Surg. 29: 155-160; discussion 160 (2003)
- Effects of CYP2D6 genotypes on plasma concentrations of risperidone and
enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N., Mihara K., Kondo T., Kubota T., Iga T., Takarada Y., De
Vries R., Kaneko S., and Tateishi T. J Clin Pharmacol. 43: 122-127 (2003)
- CYP3A4*18:It is not rare allele in Japanese population. Yamamoto T.,
Nagafuchi, N., Ozeki, T., Kubota, T., Ishikawa, H., Ogawa, S., Yamada, Y.,
Hirai, H., Iga, T. Drug Metabol Pharmacokin. 18: 167-168 (2003)
- Effect of the single CYP2C9*3 allele on pharmacokinetics and
pharmacodynamics of losartan in healthy Japanese subjects. Sekino K., Kubota
T., Okada Y., Yamada Y., Yamamoto K., Horiuchi R., Kimura K., and Iga T. Eur
J Clin Pharmacol. 59: 589-592 (2003)
- Combined therapy using Q-switched ruby laser and bleaching treatment
with tretinoin and hydroquinone for acquired dermal melanocytosis. Momosawa
A., Yoshimura K., Uchida G., Sato K., Aiba E., Matsumoto D., Yamaoka H.,
Mihara S., Tsukamoto K., Harii K., Aoyama T., and Iga T. Dermatol Surg. 29:
1001-1007 (2003)
- Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme
activity in a Japanese population. Ishiguro A., Kubota T., Sasaki H., Yamada
Y., and Iga T. Br J Clin Pharmacol. 55: 414-415 (2003)
- Sex differences in the pharmacokinetics of pioglitazone in rats. Fujita
Y., Yamada Y., Kusama M., Yamauchi T., Kamon J., Kadowaki T., and Iga T.
Comp Biochem Physiol C Toxicol Pharmacol. 136: 85-94 (2003)
- Association of troglitazone-induced liver injury with mutation of the
cytochrome P450 2C19 gene. Kumashiro R., Kubota T., Koga Y., Tanaka M.,
Inada C., Kusaba N., Yoshida H., Hisamochi A., Ide T., Tomita Y., Masumoto
N., Tanikawa K., Iga T., and Sata M. Hepatol Res. 26: 337-342 (2003)
- Effects of various CYP2D6 genotypes on the steady-state plasma
concentrations of risperidone and its active metabolite,
9-hydroxyrisperidone, in Japanese patients with schizophrenia. Mihara K.,
Kondo T., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., Kubota T., Iga
T., Takarada Y., de Vries R., and Kaneko S. Ther Drug Monit. 25: 287-293
(2003)
- Pharmacokinetic and pharmacodynamic analyses based on dopamine
D2-receptor occupancy of bromocriptine, of bromocriptine-induced
contralateral rotations in unilaterally 6-OHDA-lesioned rats. Atsumi M.,
Kawakami J., Sugiyama E., Kotaki H., Sawada Y., Sato H., Yamada Y., and Iga
T. Synapse. 50: 110-116 (2003)
- Inhibitory effect of erythromycin on potassium currents in rat
ventricular myocytes in comparison with disopyramide. Hanada E., Ohtani H.,
Hirota M., Uemura N., Nakaya H., Kotaki H., Sato H., Yamada Y., and Iga T. J
Pharm Pharmacol. 55: 995-1002 (2003)
- Potentiation of domperidone-induced catalepsy by a P-glycoprotein
inhibitor, cyclosporin A. Tsujikawa K., Dan Y., Nogawa K., Sato H., Yamada
Y., Murakami H., Ohtani H., Sawada Y., and Iga T. Biopharm Drug Dispos. 24:
105-114 (2003)
- Drug Interaction between Tacrolimus and Fluconazole in Living Related
Liver Transplant Patients Iwasa I., Sugiyama E., Yamada Y., Harihara Y.,
Makuuchi M., and Iga T. Jpn. J.TDM, 19: 33-38 (2002)
- The Genetic Polymorphism of Cytochrome P450 and Its Effect on the
Metabolic Activity in the Japanese Population Akaishi T., Kubota T., and Iga
T. Jpn J Clin Pharmacol Ther. 33 : 243-246 (2002)
- Effect of admixture of commercially available corticosteroid ointments
and/or creams on vasoconstrictor activity. Ohtani M., Yamada N., Takayama
K., Kotaki H., Etoh T., Kariya S., Uchino K., and Iga T. Yakugaku Zasshi,
122: 107-112 (2002)
- Evaluation of the permeability of corticosteroid in hairless mouse and
hairless micropig skin from admixture of commercially available
corticosteroid ointments and/or creams. Ohtani M., Kotaki H., Kariya S.,
Uchino K., and Iga T. Yakugaku Zasshi, 122: 589-594 (2002)
- Recall Information of Pharmaceuticals and Medical Devices Regarding
Legal Regulations and the Current Status Participation of the Pharmacists in
Safety Management Kageyama E., Furuiwa S., Kimura R., Orii T., and Iga
T. Jpn J Pharm Health Care Sci. 28: 435-442 (2002)
- A Survey of the Attitude of the New Graduate Pharmacists on Clinical
Trials Takayanagi R., Yamada Y., Kono M., Nakamura H., Sato H., Iga T. Jpn J
Pharm Health Care Sci. 28: 489-494 (2002)
- The construction and evaluation of the preventing method for the input
mischoice in a prescription order entry system --usefulness of a
three-character input and a warning screen display system. Watanabe M.,
Sugiura M., Seino T., Mitsunaga Y., Nakamura H., Yamada Y., Tsuchiya F., Ohe
K., and Iga T. Yakugaku Zasshi, 122: 841-847 (2002)
- A Study of Recall Information Given by Pharmaceuticals (Part 2)-Measures
of Pharmaceutical Company for Providing Information Related to Bovine
Spongiform Encephalopathy- Kageyama E., Koura S., Kimura R., Orii T., and
Iga T. Jpn J Pharm Health Care Sci. 29: 438-448 (2003)
- Creation and usefulness of the "drug information card" for support of
dispensing. Kamata S., Negishi E., Ogata A., Nakajima K., Orii T., Nakamura
H., Yamada Y., and Iga T. Yakugaku Zasshi, 123: 69-75 (2003)
- Adsorption of rhG-CSF (Filgrastim) to Extension Tube Sugiura M.,
Nakajima K., Yamada Y., and Iga T. Jpn J Pharm Health Care Sci. 29: 173-177
(2003)
- Documents for clinical trials of new drugs: results of their reviews
prior to submissions to IRB. Takayanagi R., Yamada Y., Watanabe K., Nakamura
H., Omata M., and Iga T. Yakugaku Zasshi, 123: 249-254 (2003)
- Pharmacokinetic / pharmacodynamic analysis of anti-hyperprolactinemic
effect of terguride based on dopamine D2 receptor occupancy.
Yamada Y., Irizuki N., Takayanagi R., Yamamoto K., Sawada Y., and Iga T.
Yakugaku Zasshi, 123: 255-260 (2003)
- Investigation of the cause of polyurethane catheter cracking during
constant infusion of etoposide (VP-16) injection (2) ‐Analysis of ethanol
eluting materials from catheter. Yokoyama H., Aoyama T., Nakajima K., Yamada
Y., Sato H., Chiba S., Hirai H., and Iga T.
Yakugaku Zasshi, 123: 799-803 (2003)
- The Adsorption of Granulocyte‐Colony Stimulating Factor (Nartograstim)
to a Plastic Syringe during Constant Infusion and a Method to Prevent
Adsorption Kuramoto K., Aoyama T., Sugiura M., Seino T., Yamada Y.,
and Iga T. Jpn J Pharm Health Care Sci. 29: 691-697 (2003)
- The effects of indomethacin spray on the pain of stomatitis in the
patients for hematopoietic stem cell transplantation. Nakamura T., Aoyama
T., Yanagihara Y., Yamada Y., Miyoshi A., Kanda Y., Hirai H., Furukawa T.,
and Iga T. Yakugaku Zasshi, 123: 1023-1029 (2003)
- A Study of Recall Information Given by Pharmaceuticals (Part 3)
-Usefulness of Drug Recall Information in Uwajima City Hospital-
Kageyama E., Orii T., and Iga T. Jpn J Pharm Health Care Sci.
30:113-120(2004)
- Support System for Pharmaceutical Training in Hospitals Using the
Internet and Its Shortcomings Kageyama E., Koura S., Orii T., and Iga T. Jpn
J Pharm Health Care Sci. 30:217-223(2004)
Annual Report of the Graduate School of Medicine and The Faculty of Medicine
The University of Tokyo Reports for the Period April 2002 - March 2004
|
|